Amalgamated Bank trimmed its holdings in Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR – Get Rating) by 3.7% in the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 71,009 shares of the biotechnology company’s stock after selling 2,744 shares during the period. Amalgamated Bank’s holdings in Arrowhead Pharmaceuticals were worth $3,266,000 as of its most recent filing with the Securities and Exchange Commission.
Other hedge funds and other institutional investors also recently made changes to their positions in the company. Louisiana State Employees Retirement System raised its position in Arrowhead Pharmaceuticals by 3.0% during the first quarter. Louisiana State Employees Retirement System now owns 27,600 shares of the biotechnology company’s stock valued at $1,263,000 after purchasing an additional 800 shares in the last quarter. E Fund Management Co. Ltd. acquired a new position in Arrowhead Pharmaceuticals during the first quarter valued at approximately $295,000. State of Michigan Retirement System raised its position in Arrowhead Pharmaceuticals by 1.3% during the first quarter. State of Michigan Retirement System now owns 26,770 shares of the biotechnology company’s stock valued at $1,231,000 after purchasing an additional 342 shares in the last quarter. Duality Advisers LP acquired a new position in Arrowhead Pharmaceuticals during the first quarter valued at approximately $563,000. Finally, Charles Schwab Investment Management Inc. raised its position in Arrowhead Pharmaceuticals by 1.9% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 1,049,894 shares of the biotechnology company’s stock valued at $69,608,000 after purchasing an additional 19,141 shares in the last quarter. 67.29% of the stock is currently owned by institutional investors and hedge funds.
Arrowhead Pharmaceuticals Stock Performance
Shares of Arrowhead Pharmaceuticals stock opened at $31.50 on Friday. The company has a quick ratio of 3.37, a current ratio of 3.37 and a debt-to-equity ratio of 0.16. Arrowhead Pharmaceuticals, Inc. has a twelve month low of $26.81 and a twelve month high of $84.83. The stock has a market cap of $3.33 billion, a price-to-earnings ratio of -21.28 and a beta of 1.42. The company’s fifty day moving average is $41.30 and its 200 day moving average is $39.99.
Wall Street Analysts Forecast Growth
Several research analysts have recently issued reports on ARWR shares. Morgan Stanley started coverage on shares of Arrowhead Pharmaceuticals in a report on Friday, September 9th. They set an “equal weight” rating and a $41.00 price target for the company. HC Wainwright reiterated a “buy” rating and set a $110.00 price target on shares of Arrowhead Pharmaceuticals in a report on Thursday, July 14th. Chardan Capital upped their price target on shares of Arrowhead Pharmaceuticals from $80.00 to $82.00 in a report on Friday, August 5th. Finally, The Goldman Sachs Group upped their price target on shares of Arrowhead Pharmaceuticals from $58.00 to $65.00 and gave the stock a “buy” rating in a report on Monday, August 8th. Three analysts have rated the stock with a hold rating and four have given a buy rating to the company. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $66.57.
Arrowhead Pharmaceuticals Company Profile
Arrowhead Pharmaceuticals, Inc develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes ARO-AAT, a RNA interference (RNAi) therapeutic candidate that is in Phase II clinical trial for the treatment of liver diseases associated with alpha-1 antitrypsin deficiency; ARO-APOC3, which is in phase 2b and one phase 3 clinical trial to treat hypertriglyceridemia; ARO-ANG3 that is in Phase 2b clinical trial to reduce production of angiopoietin-like protein 3; ARO-HSD, which is in Phase 1/2a clinical trial to treat liver diseases; ARO-ENaC, which is in a Phase 1/2a clinical trial to reduce production of the epithelial sodium channel alpha subunit in the airways of the lung; ARO-C3 for the treatment of complement-mediated disease that is in Phase 1/2a clinical trial; ARO-Lung2 for the treatment of chronic obstructive pulmonary disorder; ARO-DUX4 for the treatment of facioscapulohumeral muscular dystrophy; ARO-XDH to treat uncontrolled gout; ARO-COV for the treatment of COVID-19 and other pulmonary-borne pathogens; and ARO-HIF2, which is in phase 1b clinical trial to treat clear cell renal cell carcinoma.
- Get a free copy of the StockNews.com research report on Arrowhead Pharmaceuticals (ARWR)
- What Steelcase’s Earnings Say About the Return to the Office?
- The Institutions Hold On To Darden Restaurants International
- These 3 Big Dividend Payers Also Boast Strong Price Growth
- Is The Golden Age Of Homebuilding Already Over?
- Natural Gas Prices Continue To Rally, These Stocks Should Benefit
Receive News & Ratings for Arrowhead Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arrowhead Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.